knowledge -WSS

knowledge

author：leisure time 2025-09-30 00:51:04 - browse：65339

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： What a koala virus tells us about the human genome

knowledge

WSS

ALS treatment from Biogen, Ionis fails in study

Readout LOUD podcast: What to know about H5N1 bird flu

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

The United States must get value

HHS suspends federal funding for EcoHealth Alliance

Sanofi strikes deal with Novavax, boosting the vaccine maker

hotspot

knowledge

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

CVS is willing to dump 10% of its Medicare Advantage members

Trump demands the U.S. pay no more for drugs than other countries … again

The White House hikes tariffs on plastic syringes made in China

Hepatitis C has a cure — but many Americans still lack access to it

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

DIEP, the 'gold standard' of breast reconstruction, is under threat

HHS suspends federal funding for EcoHealth Alliance

explore

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Elevance, private equity launch primary care company

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

HHS suspends federal funding for EcoHealth Alliance

WuXi Biologics execs register to lobby as Congress comes for the company

Shionogi licenses Pompe disease therapy from Maze Therapeutics

explore

entertainment

knowledge

entertainment